Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 151 to 160 of 220 total matches.

A Drug Prevention of Anthracycline-Induced Cardiac Toxicity

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 1991  (Issue 852)
Cerubidine dexrazoxane for cardiotoxicity Cancer chemotherapy Adriamycin daunorubicin doxorubicin ...
Recent studies have caused concern about cardiomyopathy associated with doxorubicin (Adriamycin, and others), daunorubicin (Cerubidine, and others), idarubicin (Idamycin), mitoxantrone (Novantrone), and related anthracycline or anthraquinone anticancer drugs. Dexrazoxane (ADR-529, ICRF-187 - Adria), a piperazine derivative of ethylenediaminetetraacetic acid (EDTA), is now under investigation for prevention of this drug-induced cardiomyopathy.
Med Lett Drugs Ther. 1991 Sep 6;33(852):85-6 |  Show IntroductionHide Introduction

Irinotecan for Metastatic Colorectal Cancer

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 1997  (Issue 992)
FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS Adrucil CANCER CHEMOTHERAPY ...
Irinotecan hydrochloride (Camptosar - Pharmacia & Upjohn; formerly CPT-11) has been approved by the US Food and Drug Administration for treatment of metastatic colorectal cancer refractory to other drugs including fluorouracil (5-FU; Adrucil and others).
Med Lett Drugs Ther. 1997 Jan 19;39(992):8 |  Show IntroductionHide Introduction

In Brief: A New Indication for Abemaciclib (Verzenio) (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
following endocrine therapy and prior chemotherapy in the metastatic setting. survival (IDFS ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib (Verzenio – Lilly) has been approved by the FDA for use in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.1It was previously approved for the same indication, but patients were also required to have a Ki-67 score ≥20%. About 70% of all breast cancers are HR-positive and HER2-negative. Ki-67 is a...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e62-3   doi:10.58347/tml.2023.1673g |  Show IntroductionHide Introduction

Pegaspargase for Acute Lymphoblastic Leukemia

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 1995  (Issue 944)
can tolerate Erwinia asparaginase. TREATMENT OF ALL — Multidrug chemotherapy now can cure about 70 ...
Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for treatment of acute lymphoblastic leukemia (ALL), the most common malignancy of childhood. The new drug is recommended only for patients who have had allergic reactions to asparaginase. Asparaginase is available commercially as Elspar, which is derived from Escherichia coli. A formulation derived from Erwinia chrysanthemi is available on an investigational basis (Ogden Bioservices,...
Med Lett Drugs Ther. 1995 Mar 17;37(944):23-4 |  Show IntroductionHide Introduction

Glucarpidase (Voraxaze) for Methotrexate Toxicity

   
The Medical Letter on Drugs and Therapeutics • Mar 05, 2012  (Issue 1385)
, and in high doses can cause nephrotoxicity. Patients receiving cancer chemotherapy with high-dose ...
The FDA has approved glucarpidase (Voraxaze – BTG International) for treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Glucarpidase has been available in the US since 2007 under a compassionate use open-label treatment protocol (Clinical Trials and Consulting Services, 1-877-398-9829), which will remain in effect until the drug becomes commercially available later this year. There is currently a shortage of IV methotrexate in the US.
Med Lett Drugs Ther. 2012 Mar 5;54(1385):19-20 |  Show IntroductionHide Introduction

Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2014  (Issue 1440)
conditions, who often have difficulty tolerating chemotherapy, combining rituximab with the alkylating ...
The FDA has approved ibrutinib (eye broo' ti nib; Imbruvica – Janssen/Pharmacyclics), an oral kinase inhibitor, for second-line treatment of chronic lymphocytic leukemia (CLL). It is the first kinase inhibitor to be approved for CLL. Ibrutinib was approved earlier for second-line treatment of mantle cell lymphoma, a rare form of B-cell non-Hodgkins lymphoma.
Med Lett Drugs Ther. 2014 Apr 14;56(1440):29-30 |  Show IntroductionHide Introduction

Omidubicel (Omisirge) for Neutrophil Recovery Following Myeloablative Conditioning Therapy (online only)

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
transplantation, patients receive myeloablative conditioning therapy with high-dose chemotherapy ...
The FDA has approved omidubicel-onlv (Omisirge – Gamida Cell), a nicotinamide-modified, allogeneic hematopoietic progenitor cell therapy derived from cord blood, to reduce the time to neutrophil recovery and the risk of infection in patients ≥12 years old with hematologic malignancies who will undergo umbilical cord blood transplantation following myeloablative conditioning therapy. Hematopoietic progenitor cell (HPC) umbilical cord products (e.g., Allocord, Clevecord, Ducord) have been available in the US for years for the same indication. Cord blood banks also supply cord...
Med Lett Drugs Ther. 2023 May 29;65(1677):e93-4   doi:10.58347/tml.2023.1677h |  Show IntroductionHide Introduction

Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
to receive osimertinib 80 mg or placebo once daily, with or without standard adjuvant chemotherapy ...
The FDA has approved osimertinib (Tagrisso – AstraZeneca), an oral kinase inhibitor, for adjuvant treatment of non-small cell lung cancer (NSCLC) after tumor resection in adults who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Osimertinib is the first targeted therapy to be approved in the US for this indication. The drug was previously approved for first-line treatment of adults with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations and for treatment of EGFR T790M mutation-positive NSCLC in adults whose disease progressed...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e131-2   doi:10.58347/tml.2023.1682c |  Show IntroductionHide Introduction

Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025  (Issue 1720)
evaluating zanidatamab in combination with chemotherapy, with or without a programmed death receptor-1 (PD ...
Zanidatamab-hrii (Ziihera – Jazz), a bispecific HER2-directed antibody, has received accelerated approval from the FDA for treatment of unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer in patients who received prior therapy. Biliary tract cancer includes gallbladder cancer and intrahepatic and extrahepatic cholangiocarcinoma. Zanidatamab is the first dual HER2-targeted therapy to be approved in the US for this indication. Accelerated approval was based on the overall response rate and duration of response.
Med Lett Drugs Ther. 2025 Jan 20;67(1720):e16-7   doi:10.58347/tml.2025.1720f |  Show IntroductionHide Introduction

Treatment of Clostridium Difficile Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 1989  (Issue 803)
and Chemotherapy, Houston, Sept 1989, page 107). Vancomycin has been used more extensively for seriously ill ...
The gram-positive bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea and pseudomembranous colitis (R Fekety in GL Mandell et al, eds, Principles and Practice of Infectious Diseases, 3rd ed, New York:Churchill Livingstone, 1990, page 863). C. difficile colitis usually develops during or soon after antibiotic treatment. Virtually any antimicrobial agent can cause the disorder, but clindamycin, ampicillin and the cephalosporins have been implicated most frequently. Pseudomembranous colitis was recently reported in five patients who had ...
Med Lett Drugs Ther. 1989 Oct 20;31(803):94-5 |  Show IntroductionHide Introduction